Source:http://linkedlifedata.com/resource/pubmed/id/16115621
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2006-1-27
|
pubmed:abstractText |
The aim of the present study was to evaluate the effect of latanoprost monotherapy on the aqueous humour concentrations of TGF-beta1, MMP-2, TIMP-2, MMP-9 and gelatinolytic activity in patients treated for exfoliative glaucoma (XFG). Aqueous samples from 50 XFG patients treated with latanoprost and 50 age-matched XFG patients treated with timolol were collected during phacoemulsification cataract surgery. The concentrations of TGF-beta1, MMP-2, TIMP-2, MMP-9 and gelatinase activity were determined by commercial immunoassays. The mean active TGF-beta1 concentration in the aqueous was significantly lower in XFG patients treated with latanoprost compared with those treated with timolol (3.1 +/- 0.65 vs 13.4 +/- 1.5 pg ml(-1)); (P = 0.0014). The mean total MMP-2 concentration was lower in latanoprost treated patients (31.75 +/- 3.8 vs 81.5 +/- 7.2 ng ml(-1)); (P < 0.0001). The TIMP-2 concentration was also lower in XFG-latanoprost treated patients (73.8 +/- 6.81 vs 101.28 +/- 7.29 ng ml(-1)); (P = 0.0096). Latanoprost monotherapy has a marked effect on the aqueous concentration of TGF-beta1, MMP-2 and TIMP-2 in XFG patients. A better understanding of its effect on the pathobiology of the disease may lead to its earlier use in the disease process to prevent progression from XFS to XFG.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Gelatinases,
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandins F, Synthetic,
http://linkedlifedata.com/resource/pubmed/chemical/TGFB1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Timolol,
http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta,
http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta1,
http://linkedlifedata.com/resource/pubmed/chemical/latanoprost
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0014-4835
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
82
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
319-22
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16115621-Adrenergic beta-Antagonists,
pubmed-meshheading:16115621-Aged,
pubmed-meshheading:16115621-Antihypertensive Agents,
pubmed-meshheading:16115621-Aqueous Humor,
pubmed-meshheading:16115621-Case-Control Studies,
pubmed-meshheading:16115621-Gelatinases,
pubmed-meshheading:16115621-Glaucoma,
pubmed-meshheading:16115621-Humans,
pubmed-meshheading:16115621-Prostaglandins F, Synthetic,
pubmed-meshheading:16115621-Timolol,
pubmed-meshheading:16115621-Transforming Growth Factor beta,
pubmed-meshheading:16115621-Transforming Growth Factor beta1
|
pubmed:year |
2006
|
pubmed:articleTitle |
Latanoprost therapy reduces the levels of TGF beta 1 and gelatinases in the aqueous humour of patients with exfoliative glaucoma.
|
pubmed:affiliation |
A University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece. konstas@med.auth.gr
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|